|
| 36870853 | Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. | Eur Urol Oncol | 2023 |
| 37728512 | The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. | Cancer Res Commun | 2023 |
| 37141981 | High Recurrence for HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiation Therapy to Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical Trial. | Int J Radiat Oncol Biol Phys | 2023 |
| 36880064 | Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. | Clin Transl Radiat Oncol | 2023 |
| 34990726 | Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. | Radiother Oncol | 2022 |
| 35842534 | Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. | Ann Surg Oncol | 2022 |
| 35397740 | Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease. | Ann Surg Oncol | 2022 |
| 35493121 | Viral Burden and Clearance in Asymptomatic COVID-19 Patients. | Open Forum Infect Dis | 2022 |
| 35849286 | ASO Visual Abstract: Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. | Ann Surg Oncol | 2022 |
| 35115362 | Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. | J Immunother Cancer | 2022 |
| 31502153 | Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. | Methods Mol Biol | 2020 |
| 32054730 | A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. | Clin Cancer Res | 2020 |
| 32461072 | Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. | Eur Urol | 2020 |
| 32509582 | Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. | Front Oncol | 2020 |
| 30536617 | Functional microRNA binding site variants. | Mol Oncol | 2019 |
| 31272507 | Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. | J Immunother Cancer | 2019 |
| 31185482 | Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study. | Gynecol Obstet Invest | 2019 |
| 31128144 | Enhancing Career Paths for Tomorrow's Radiation Oncologists. | Int J Radiat Oncol Biol Phys | 2019 |
| 30897768 | Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics. | Noncoding RNA | 2019 |
| 30796975 | Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. | Pract Radiat Oncol | 2019 |
| 30932013 | The KRAS-variant and its impact on normal breast epithelial cell biology. | Cell Death Differ | 2019 |
| 29050918 | Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. | Clin Breast Cancer | 2018 |
| 29518404 | MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. | Hum Pathol | 2018 |
| 29479673 | The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality. | Cancer | 2018 |
| 28964588 | Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. | Int J Radiat Oncol Biol Phys | 2018 |
| 27321180 | cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. | Oncogene | 2017 |
| 28702891 | Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. | Breast Cancer Res Treat | 2017 |
| 28900044 | Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in <i>KRAS</i> mutant mesenchymal-like NSCLC cells. | Sci Signal | 2017 |
| 28899898 | Investigating the association of rs2910164 with cancer predisposition in an Irish cohort. | Endocr Connect | 2017 |
| 28006059 | The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. | JAMA Oncol | 2017 |
| 26996824 | miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage. | Nat Commun | 2016 |
| 29657269 | Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9. | Noncoding RNA | 2016 |
| 29657267 | The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. | Noncoding RNA | 2016 |
| 27621267 | Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein. | Mol Cancer Res | 2016 |
| 26711112 | Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. | Nat Genet | 2016 |
| 24909162 | Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. | Oncogene | 2015 |
| 25961464 | Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. | Cell Cycle | 2015 |
| 25539919 | Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. | Nucleic Acids Res | 2015 |
| 24246724 | Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. | Int J Radiat Oncol Biol Phys | 2014 |
| 25485042 | A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA. | J Radiat Oncol | 2014 |
| 25081901 | A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. | Ann Oncol | 2014 |
| 25183481 | A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. | Clin Cancer Res | 2014 |
| 24732316 | The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. | PLoS One | 2014 |
| 24819663 | Radiation therapy oncology group gynecologic oncology working group: comprehensive results. | Int J Gynecol Cancer | 2014 |
| 24915755 | A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. | BMC Cancer | 2014 |
| 24552817 | Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. | Cell Cycle | 2014 |
| 22658441 | A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer. | Int J Radiat Oncol Biol Phys | 2013 |
| 23614619 | SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. | Crit Rev Oncog | 2013 |
| 23552804 | Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. | Int J Gynecol Cancer | 2013 |
| 23221733 | COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. | Int J Gynecol Cancer | 2013 |